Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor

Current Topics in Medicinal Chemistry

Volumn 6, Issue 5, 2006, Pages 435-460

  Lackey, Karen E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Epidermal growth factor receptor tyrosine kinase (erbB 1); erbB 2 tyrosine kinase; GW2016; Lapatinib; Quinazoline series

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GW 0277; GW 2764; GW 2974; GW 3340; GW 4049; GW 4263; GW 4783; GW 5289; GW 5945; GW 8295; GW 9263; GW 9525; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; NONHUMAN; PHYSICAL CHEMISTRY; RECEPTOR BINDING; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646125891     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776743156     Document Type: Review

References (105)

1. Manning, G.; Plowman, G. D.; Hunter, T.; Sudarsanam, S. Evolution of protein kinase signaling from yeast to man. Trends in Biochemical Sciences 2002, 27(10), 514-520.
2. Wolf, I.; Seger, R. The mitogen-activated protein kinase signaling cascade: From bench to bedside. Israel Medical Association Journal 2002, 4(8), 641-647.
3. Li, X.; Ketter, T. A.; Frye, M. A. Synaptic, intracelular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? Journal of Affective Disorders 2002, 69(1-3), 1-14.
4. Srivastava, A. K. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: A potential role in the pathogenesis of vascular dysfunction in diabetes (Review). International Journal of Molecular Medicine 2002, 9(1), 85-89.
5. Force T.; Kuida, K.; Namchuk, M.; Parang, K.; Kyriakis, J. M. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004, 109(10), 1196-205.
6. Riese, D. J.; Stern, D. F. Specificity within the EGF family/ErbB Receptor Family signaling network BioEssays 1998, 20, 41-48.
7. Hopkins, A. L.; Groom, C. R. The Druggable Genome. Nature Reviews Drug Discovery 2002, 1, 727.
8. Chapter 2: Fedi, P.; Aaronson, S. A. Signal Transduction Through Tyrosine Kinase Growth Factor Receptors, 27 - 38. Chapter 12: Clark, G. J.; O'Bryan, J. P.; Der, C. J. Ras Signaling and Transformation, 213 - 230. In Signaling Networks and Cell Cycle Control: The molecular Basis of Cancer and Other Diseases; Gutkind, J. S.; Ed. Humana Press, Inc.; Totowa, New Jersey, 2000.
9. Parang, K.; Sun, G. Design Strategies for protein kinase inhibitors. Current Opinion in Drug Discovery & Development 2004, 7(5), 617-629.
10. Tang, J.; Shewchuk, L. M.; Sato, H.; Hasegawa, M.; Washio, Y.; Nishigaki, N. Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and x-ray crystallographic analysis. Bioorganic & Medicinal Chemistry Letters 2003, 13(18), 2985-2988.
11. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Current Medicinal Chemistry 1999, 6(9), 775-805.
12. Pirard, B.; Pickett, S. D. Classification of Kinase Inhibitors Using BCUT Descriptors. Journal of Chemical Information and Computer Sciences 2000, 40(6), 1431-1440.
13. Rowinsky, E. K. Targeting Signal Transduction. In Horizons in Cancer Therapeutics: From Bench to Bedside; 2001, 2(2), p2-35.
14. London, C. Kinase Inhibitors in Cancer Therapy. Veterinary and Comparative Oncology 2004, 2(4), 177-193.
15. Paul, M. K.; Mukhopadhyay, A. K. Tyrosine Kinase - role and significance in cancer. International Journal of Medical Sciences 2004, 1(2), 101-115.
16. Yarden, Y.; Sliwkowski, M. X. Untangling the erbB signalling network. Nature Reviews 2001, 2, 127-137.
17. Alroy I.; Yarden, Y. The erbB Signaling Network in Embryogenesis and Oncogenesis: Signal Diversification through Combinatorial Ligand-Receptor Interactions FEBS Lett. 1997 410, 83-86.
18. Klapper, L. N.; Kirschbaum, M. H.; Sela, M.; Yarden, Y. Biochemical and Clinical Implications of the erbB/HER Signaling Network of Growth Factor Receptors. Adv. Cancer Res. 2000, 77, 25-79.
19. Riese, D. J. 2nd; Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays : news and reviews in molecular, cellular and developmental biology 1998, 20(1), 41-8.
20. Moghal, N.; Sternberg, P. W. Multiple positive and negative regulators of signaling by the EGF-receptor. Current Opinion in Cell Biology 1999, 11(2), 190-6.
21. Albanell, J.; Ross, J.S. Epidermal growth factor receptor and other growth factors and receptors. Molecular Oncology of Breast Cancer 2005, 256-275.
22. Esteva, F. J. Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer. The Oncologist 2004, 9(suppl 3), 4-9.
23. Baselga, J.; Averbuch, S. G. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000, 60(suppl. 1), 33-40.
24. de Bono, J. S.; Rowinsky, E. K. The ErbB receptor family: a therapeutic target for cancer. Trends in Molecular Medicine 2002, 8(4), S19-S26.
25. Tiseo, M.; Loprevite, M.; Ardizzoni, A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Current Medicinal Chemistry: Anticancer agents 2004, 4(2), 139-148.
26. Ranson, M. Epidermal Growth Factor Receptor Tyrosine kinase inhibitors. British Journal of Cancer 2004, 90(12), 2250-2255.
27. Bridges, A. J. Chemical Inhibitors of Protein Kinases. Chem. Rev. 2001, 101, 2541-2571.
28. Dumas, J. Growth factor receptor kinase inhibitors: Recent progress and clinical impact. In Current Opinion in Drug Discovery and Development 2001, 4(4), 378-389.
29. Cockerill, S. G.; Lackey, K. E. Small Molecule Inhibitors of the Class 1 Receptor Tyrosine Kinase Family. Current Topics in Medicinal Chemistry 2002, 2(9), 1001-1010.
30. Pearson, M. A.; Fabbro, D. Targeting protein kinases in cancer therapy: a success? Expert Review of Anticancer Therapy 2004, 4(6), 1113-1124.
31. Lichtner, R. B.; Menrad, A.; Sommer, A.; Klar, U.; Schneider, M. R. Signaling-inactive Epidermal Growth Factor Receptor/Ligand Complexes in Intact Carcinoma Cells by Quinazoline Tyrosine Kinase Inhibitors. Cancer Research 2001, 61, 5790-5795.
32. Brignola, P. S.; Lackey, K.; Kadwell, S. H.; Hoffman, C.; Horne, E.; Carter, H. L.; Stuart, J. D.; Blackburn, K.; Moyer, M. B.; Alligood, K. J.; Knight, W. B.; Wood, E. R. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains: demonstration of differential sensitivity to kinase inhibitors. Journal of Biological Chemistry 2002, 277(2), 1576-1585.
33. Gibson, K. H.; Brundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumor activity of novel quinazolines. Bioorganic & Medicinal Chemistry Letters 1997, 7(21), 2723-2728.
34. Traxler, P. Tyrosine Kinase Inhibitors in Cancer Treatment (part II), Expert Opinions in Therapeutic Patents. 1998, 8, 1599-1625.
35. Traxler, P.; Furet, P. Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacology and Therapeutics 1999, 82, 195-206.
36. Pandey, A.; Volkots, D. L.; Seroogy, J. M.; Rose, J. W.; Yu, J-C.; Lambing, J. L.; Hutchaleelaha, A.; Hollenbach, S. J.; Abe, K.; Giese, N. A.; Scarborough, R. M. Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family. J. Med Chem. 2002, 45(17), 3772-3793.
37. Singh, P.; Kumar, R. Inhibitors of the epidermal growth factor receptor protein tyrosine kinase. A quantitative structure activity relationship analysis. J. Enzyme Inhibition 1998, 13(2), 125-134.
38. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulli, A. L.; Hsu, C-Y. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p561ck and EGF-R tyrosine kinase activity. Bioorganic & Medicinal Chemistry Letters 1997, 7(4), 417-420.
39. Cockerill, G. S.; Stubberfield, C.; Stables, J.; Carter, M.; Guntrip, S.; Smith, K.; McKeown, S.; Shaw, R.; Tapley, P.; Thomsen, L.; Affleck, K.; Jowett, A.; Hayes, D.; Willson, M.; Woollard, P.; Spalding, D. Indazolylamino Quinazolines and Pyridopyrimidines as Inhibitors of the EGFr and c-erbB-2. Bioorg. Med. Chem. Lett. 2001, 11(11), 1401-1405.
40. Rusnak, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R. J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K. E. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Research 2001, 61(19), 7196-7203.
41. Hunt, J. T.; Mitt, T.; Borzilleri, R.; Gullo-Brown, J.; Fargnoli, J.; Fink, B.; Han, W-C.; Mortillo, S.; Vite, G.; Wautlet, B.; Wong, T.; Yu, C.; Zheng, X.; Bhide, R. Discovery of the Pyrrolo[2,1-f][1,2,4]triazine nucleus as a New Kinase Inhibitor Template. J. Med. Chem. 2004, 47(16), 4054-4059.
42. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogs as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39(4), 918-928.
43. Dickerson, SH; Emerson, HK; Hinkle, KW; Hornberger, KR; Sammond, DM; Smith, S; Hubbard, RD; Petrov, KG; Reno, MJ; Stevens, KL; Uehling, DE, Waterson, AG. Preparation of thienopyrimidines as inhibitors of erbB kinases 2004, PCT appl. WO2004112714.
44. Badiang, J. G.; Dickerson, S. H.; Donaldson, K. H.; Hinkle, K. W.; Hornberger, K. R.; Petrov, K. G.; Reno, M. J.; Stevens, K. L.; Uehling, D. E., Waterson, A. G. Preparation of thienopyrimidine derivatives as erbB kinase inhibitors 2005, PCT appl. WO 2005007083.
45. Boschelli, D. H. 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors - an update. Medicinal Chemistry Reviews - Online 2004, 1(4), 457-463.
46. Cockerill, G. S.; Carter, M. C.; McKeown, S. K.; Vile, S.; Page, M. J.; Hudson, A. T.; Barraclough, P.; Franzmann, K. W. 1997, PCT application WO9703069.
47. Traxler, P. Tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Pat 1998, 8(12), 1599-1625.
48. Himmelsbach, F.; Langkopf, E.; Jung, B.; Metz, T.; Solca, F.; Blech, S. Preparation of aminoquinazolines and aminoquinolines as epidermal growth factor receptor signal transduction inhibitors. 2000, PCT Appl. WO 0051991.
49. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Gree, L. R. Epidermal Growth Factor Receptor Tyrosine Kinase Investigation of Catalytic Mechanism, Structure-based Searching and Discovery of a Potent Inhibitor. Biochem. Pharmacol 1994, 48, 639-666.
50. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; Diorio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research 1997, 57(21), 4838-4848.
51. Zhang, Y-M.; Cockerill, S.; Guntrip, S. G.; Rusnak, D.; Smith, K.; Vanderwall, D.; Wood, E. R.; Lackey, K. E. Synthesis and SAR of Potent EGFR/ErbB2 Dual Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14(1), 111-114.
52. Gaul, M. D.; Guo, Y.; Affleck, K.; Cockerill, G. S.; Gilmer, T. M.; Griffin, R. J.; Guntrip, S.; Keith, B. R.; Knight, W. B.; Mullin, R. J.; Murray, D. M.; Rusnak, D. W.; Smith, K.; Tadepalli, S.; Wood, E. R.; Lackey, K. Discovery and Biological Evaluation of Potent Dual ErbB-2/ EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines Bioorg. Med. Chem. Lett. 2003, 13(4), 637-640.
53. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L. Studies leading to the identification of ZD-1839 (IressaTM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett., 2001, 11(14), 1911-1914.
54. Tang, P. C.; Mcmahon, G. Quinazolines and pharmaceutical compositions. 1996, PCT Int. Appl. WO 9640648.
55. Nakamura, K.; Yamamoto, A.; Kamishohara, M.; Takahashi, K.; Taguchi, E.; Miura, T.; Kubo, K.; Shibuya, M.; Isoe, T. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Molecular Cancer Therapeutics 2004, 3(12), 1639-1649.
56. Ple, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennell, M.; Allen, J.; Lambert-van der Brempt, C.; Costello, G. Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src. J. Med. Chem. 2004, 47(4), 871-887.
57. Pratt, D. J.; Endicott, J. A.; Noble, M. E. M. The role of structure in kinase-targeted inhibitor design, Current Opinion in Drug Discovery & Development 2004, 7(4), 428-436.
58. Breitenlechner, C.; Gassel, M.; Engh, R.; Bossemeyer, D. Structural Insights into AGC kinase inhibition. Oncology Research 2004, 14(6), 267-278.
59. Rusnak, D. W.; Lackey, K. E.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B.; Murray, D. M.; Mullin, R. J.; Knight, W. B.; Gilmer, T. M. The Effects of the Novel, reversible EGFR/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2001, 1(2), 85-94.
60. Modjtahedi, H., Affleck, K., Stubberfield, C., and Dean, C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. International Journal of Oncology 1998, 13, 335-342.
61. Pasleau, F.; Grooteclaes, M.; Gol-Winkler, R. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 1993, 8, 849-854.
62. Harris, R. A.; Eichholtz, T. J.; Hiles, I. D.; Page, M. J.; O'Hare, M. J. New Model of ErbB-2 Over-Expression in Human Mammary Luminal Epithelial Cells. International Journal of Cancer 1999, 80(3), 477-484.
63. Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T.; Mitsudomi, T. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications. Cancer Research 2004, 64, 8919-8923.
64. Keith, B. R.; Allen, P. P.; Alligood, K. J.; Crosby, R. M.; Lackey, K.; Gilmer, T. M.; Mullin, R. J. Anti-tumor Activity of GW2016 in the ErbB-2 Positive Human Breast Cancer Xenograft, BT474 Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting; 2001.
65. Mullin, R. J.; Alligood, K. J.; Allen, P. P.; Crosby, R. M.; Keith, B. R.; Lackey, K. E.; Gilmer, T. M.; Griffin, R. J.; Murray, D. M.; Tadepalli, S. M. Antitumor Activity of GW2016 in the EGFR Positive HN5 Human Head and Neck Cancer Xenograft. Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting; 2001.
66. Cockerill, G. S.; Lackey, K. Preparation of Anilinoquinazolines as protein tyrosine kinase inhibitors, 2001, PCT appl. WO2001004111.
67. Carter, M. C.; Cockerill, G. S.; Guntrip, S. B.; Lackey, K. E.; Smith, K. J. Bicyclic heteroaromatic compounds [quinazolinamines, pyridopyrimidines, and analogs] useful as protein tyrosine kinase inhibitors. PCT appl. 1999, WO 9935146.
68. Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J. Preparation of bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. 1998, PCT appl. WO9802438.
69. Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J. Preparation of bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. 1998, PCT appl. WO9802437.
70. Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J. Preparation of bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. 1998, PCT appl. WO9802434.
71. Cockerill, G. S.; Lackey, K. E. Preparation of quinazolinylamines and analogs as protein tyrosine kinase inhibitors. 1999, PCT Appl. WO9935132.
72. Carter, M. C.; Cockerill, G. S.; Guntrip, S. B.; Lackey, K. E.; Smith, K. J. Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors. 2000, Brit. UK Pat. Appl. GB 2345486.
73. Cockerill, G. S.; Guntrip, S. B.; Mckeown, S. C; Page, M. J.; Smith, K. J.; Vile, S.; Hudson, A. T.; Barraclough, P.; Franzmann, K. W. 1997, WO Patent 9,713,771.
74. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002; 277, 46265-72.
75. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43(1), 133-138.
76. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationship Between Protein Conformation, Inhibitor Off-rate, and Receptor Activity in Tumor Cells. Cancer Research 2004, 64(18), 6652-6659.
77. Kunkel, E. J.; Plavec, I.; Nguyen, D.; Melrose, J.; Rosler, E. S.; Kao, L. T.; Wang, Y.; Hytopoulos, E.; Bishop, A. C.; Bateman, R.; Shokat, K. M.; Butcher, E. C.; Berg, E. L. Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based Models. Assay and Drug Development Technologies 2004, 2(4), 431-441.
78. Glennon, K. C.; Affleck, K.; Cai, Z.; Cockerill, S. G.; Dickerson, S.; Gauthier, C. A.; Griffin, R. J.; Keith, B. R.; Knight, W. B.; Mullin, R. J.; Rusnak, D. W.; Tadepalli, S. M.; Wissel, P. S.; Wood, E. R.; Zhang, Y. Structure Activity Relationship Studies Around the Core 6-Furanyl Quinazoline Template for Optimization of EGFR and ErbB-2 Tyrosine Kinase Inhibition Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting, 2001.
79. Lackey, K.; Gaul, M. D.; Affleck, K.; Alligood, K. J.; Cai, Z.; Cockerill,G. S.; Crosby, R. M.; Gilmer, T. M.; Griffin, R. J.; Guo, Y.; Keith, B. R.; Knight, W. B.; Mullin, R. J.; Murray, D. M.; Rusnak, D. W.; Tadepalli, S.; Wood, E. R. Discovery and Biological Evaluation of Potent Dual ErbB-2/Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting; 2001.
80. Mullin, R. J. Discovery and profile of GW572016, a dual reversible EGFR/ ErbB-2 tyrosine kinase inhibitor. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003.
81. Leeson, P. D.; Davis, A. M.; Steele, J. Drug-like properties: guiding principles for design - or chemical prejudice? Drug Discovery Today: Technologies 2004, 1(3), 189-195.
82. Walters, W. P.; Ajay, Murcko, M. A. Recognizing molecules with drug-like properties. Current Opinion in Chemical Biology 1999, 3(4), 384-7.
83. Di, L.; Kerns, E. H. Profiling drug-like properties in discovery research. Current Opinion in Chemical Biology 2003, 7(3), 402-408.
84. Guo, Y.; Shen, H. PKa, Solubility, and lipophilicity: assessing physicochemical properties of lead compounds. Optimization in Drug Discovery 2004, 1-17.
85. Li, A. P. In vitro approaches to evaluate ADMET drug properties, Current Topics in Medicinal Chemistry 2004, 4(7), 701-706.
86. Di, L.; Kerns, E. H.; Hong, Y.; Kleintop, T. A.; McConnell, O. J.; Huryn, D. M. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J. of Biomolecular Screening 2003, 8(4), 453-462.
87. Carter, M. C.; Cockerill, G. S.; Guntrip, S. B.; Lackey, K. E.; Smith, K. J. Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors. 2000, Brit. UK Pat. Appl. GB 2345486.
88. McClure, M. S.; Osterhout, M. H.; Roschangar, F.; Sacchetti, M. J. Preparation of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases. 2002, PCT Int. Appl. WO 2002002552.
89. McClure, M. S.; Roschangar, F.; Hodson, S. J.; Millar, A.; Osterhout, M.H. A Practical One-Pot Synthesis of 5-aryl-2-furaldehydes. Synthesis 2001, 11, 1681-1685.
90. McClure, M. S.; Glover, B.; McSorley, E.; Millar, A.; Osterhout, M. H.; Roschangar, F. Regioselective Palladium Catalyzed Arylation of 2-Furaldehyde. Organic Letters 2001, 3(11), 1677-1680.
91. Sacchetti, M. Determining the relative physical stability of anhydrous and hydrous crystal forms of GW2016. International Journal of Pharmaceutics 2004, 273(1-2), 195-202.
92. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology 2005, 23(3), 329-336.
93. Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L-H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21(41), 6255-6263.
94. Tenzer, A.; Zingg, D.; Rocha, S.; Hemmings, B.; Fabbro, D.; Glanzmann, C.; Schubiger, P. A.; Bodis, S.; Pruschy, M. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 2001, 61, 8203.
95. Albanell, J.; Codony-Servat, J.; Rojo, F.; Del Campo, J. M.; Sauleda, S.; Anido, J.; Raspall, G.; Giralt, J.; Rosello, J.; Nicholson, R. I.; Medelsohn, J.; Baselga, J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61, 6500-6510.
96. Spector N. L.; Xia, W.; Burris, H. 3rd; Hurwitz, H.; Dees, E. C.; Dowlati, A.; O'neil, B.; Overmoyer, B.; Marcom, P. K.; Blackwell, K. L.; Smith, D. A.; Koch, K. M.; Stead, A.; Mangum, S.; Ellis, M. J.; Liu, L.; Man, A. K.; Bremer, T. M.; Harris, J.; Bacus, S. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. Journal of Clinical Oncology 2005, 23(11), 2502-12.
97. Blencke, S.; Ulrich, A.; Daub, H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol Chem 2003, 278, 15435-40.
98. Sawyer, T. K. Novel Oncogenic protein kinase inhibitors for cancer therapy. Current Medicinal Chemistry: Anti-cancer agents 2004, 4(5), 449-455.
99. Bence, A. K.; Anderson, E. B.; Halepota, M. A.; Doukas, M. A.; DeSimone, P. A.; Davis, George, A.; Smith, D. A.; Koch, K. M.; Stead, A. G.; Mangum, S.; Bowen, C. J.; Spector, N. L.; Hsieh, S.; Adams, V. R. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investigational New Drugs 2005, 23(1), 39-49.
100. Burris, H. A., III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004, 9(Suppl. 3), 10-15.
101. Maung, K.; O'Shaughnessy, J. A. Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: Promising activity in pretreated advanced breast cancer. Clinical Breast Cancer 2004, 4(6), 398-400.
102. Ellis, M. Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition. The Oncologist 2004, 9(suppl 3), 20-26.
103. Chu, I.; Blackwell, K.; Chen, S.; Slingerland, J. The dual ErbB1/ErbB2 Inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Research 2005, 65(1), 18-25.
104. Xia, W.; Liu, L-H.; Ho, P.; Spector, N. L. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23(3), 646-653.
105. Affleck, K.; Allen, P.; Alligood, K. J.; Cai, Z.; Carter, M. C.; Cockerill, G. S.; Crosby, R. M.; Dickerson, S.; Frye, S. V.; Gaul, M.; Gauthier, C.; Gilmer, T. M.; Glennon, K.; Griffin, R.; Guntrip, S. B.; Guo, Y.; Johnson, N. W.; Keith, B. R.; Knight, W. B.; Luzzio, M. J.; Mook, R. A.; Mullin, R. J.; Murray, D. M.; Rusnak, D. W.; Tadepalli, S. M.; Sinhababu, A. K.; Smith, K. J.; Wood, E. R.; Zhang, Y.; Lackey, K. The Discovery of a New Anti-Cancer Agent GW2016: a Potent, Dual EGFR/ ErbB-2 Tyrosine Kinase Inhibitor Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting; 2001.